CIN-109

CIN-109, CIN-110, CIN-209 and CIN-210 are series of monotherapy and combination treatments for obesity.

CIN-109
Phase 2
CIN-110
Phase 1
CIN-209
Pre-clinical
CIN-210
Pre-clinical

CIN-109, CIN-110, CIN-209, CIN-210
OVERVIEW:

CinFina’s portfolio of obesity therapeutics include mono- and combination- therapies designed to support healthy weight loss. The portfolio was licensed from Janssen Pharmaceuticals and includes:

For more information, please vist www.cinfina.com

OBESITY
Metrics:

<10% of adults with obesity are currently using or have ever used anti-obesity therapies
KFF.org Poll 2023

40% Loss in lean body mass observed with GLP-1 therapy
Wilding JP et al, NEJM, 2021

50% of patients with diabetes discontinue GLP-1 therapies within 1 year. 70% quit within year 2. Tolerability continues to be the major reason.
Weiss Tet al, BMJ Open Diab Res Care 2022

66% Of the weight is regained within a year off GLP-1.
Wilding JP et al, Diab Obesity and Metab, 2022

Sources:
Bryan, Stierman, et al. NHSR 158. National Health and Nutrition Examination Survey 2017–March 2020 Pre-Pandemic Data Files. 14 June 2021, stacks.cdc.gov/view/cdc/106273.

Morgan Stanley

Fujioka, K, et al. “The Relationship between Early Weight Loss and Weight Loss at 1 Year with Naltrexone ER/Bupropion ER Combination Therapy.” International Journal of Obesity, vol. 40, no. 9, 22 June 2016, pp. 1369–1375, 10.1038/ijo.2016.67. Accessed 15 Apr. 2020.

REASONS
TO BELIEVE

GDF-15
PYY
Both programs offer dual agonist (GDF-15 / GLP-1 and PYY / GLP-1) next generation therapies, giving patients and physicians options with different mechanisms of action in a single injection

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES